Item 8.01 Other Events.

On December 8, 2020, we entered into an underwriting agreement (the "Underwriting Agreement") with SVB Leerink LLC, Credit Suisse Securities (USA) LLC, Barclays Capital Inc., and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters named therein (collectively, the "Underwriters"), relating to the issuance and sale in a public offering of 8,110,000 shares of our common stock, par value $0.0001 per share. The price to the public in the offering is $37.00 per share and the Underwriters have agreed to purchase the shares from us pursuant to the Underwriting Agreement at a price of $34.78 per share. The net proceeds to us from the offering are expected to be approximately $281.7 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. The closing of the offering is expected to occur on December 11, 2020, subject to customary closing conditions. In addition, we granted the Underwriters a 30-day option to purchase up to 1,216,500 additional shares of our common stock at the public offering price, less the underwriting discounts and commissions.

The Underwriting Agreement contains customary representations, warranties and agreements by us, customary conditions to closing, indemnification obligations of us and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by such parties.

The offering is being made pursuant to our effective registration statement on Form S-3 and accompanying prospectus (Registration Statement No. 333-251172), previously filed with the Securities and Exchange Commission ("SEC"), and a prospectus supplement thereunder. A copy of the Underwriting Agreement is filed as Exhibit 1.1 to this report, and the foregoing description of the terms of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to such exhibit. A copy of the opinion of Cooley LLP relating to the legality of the issuance and sale of the shares in the offering is attached as Exhibit 5.1 hereto.

On December 7, 2020, we issued a press release announcing the commencement of the offering and on December 8, 2020 we issued a press release announcing that we had priced the offering. Copies of these press releases are attached as Exhibits 99.1 and 99.2 hereto, respectively.

Forward-Looking Statements

Certain statements contained in this report are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include, without limitation, statements about our expectations with respect to the completion, timing and size of the public offering and the expected net proceeds from the offering. Words such as "will", "expect", "may," "goal," "potential" and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. For such statements, we claim the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from our expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the public offering and the COVID-19 global pandemic. Additional factors that could cause actual results to differ materially from those stated or implied by our forward-looking statements are disclosed in our filings with the SEC, including in the section captioned "Risk Factors" in our quarterly report on Form 10-Q for the quarterly period ended September 30, 2020. These forward-looking statements represent our judgment as of the time of this report. We disclaim any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.


--------------------------------------------------------------------------------

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.



Exhibit
  No.                                    Description

 1.1          Underwriting Agreement, dated December 8, 2020, by and among Kura
            Oncology, Inc., SVB Leerink LLC, Credit Suisse Securities (USA) LLC,
            Barclays Capital Inc., and Stifel, Nicolaus & Company, Incorporated,
            as representatives of the several underwriters named therein.

 5.1          Opinion of Cooley LLP.

23.1          Consent of Cooley LLP (included in Exhibit 5.1).

99.1          Press Release, dated December 7, 2020, titled "Kura Oncology
            Announces Commencement of Public Offering of Common Stock".

99.2          Press Release, dated December 8, 2020, titled "Kura Oncology
            Announces Pricing of $300 Million Public Offering of Common Stock".

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses